About us Get involved Research COVAX Marketplace News & stories Careers Contact Support CEPI Join our coalition and help us create a future in which epidemics are no longer a threat to humanity. INVEST NOW CEPI’s $3.5 billion plan to End Pandemics CEPI has launched its $3.5bn plan to dramatically reduce or even eliminate the future risk of pandemics and epidemics, potentially averting millions of deaths and trillions of dollars in economic damage. CEPI’s five-year plan sets out ambitious initiatives to build a future world that is better equipped to deal with these devastating diseases. As part of the plan, CEPI announced its “moonshot” objective to help compress vaccine development timelines to 100 days, about a third of the time that it took the world to develop a COVID-19 vaccine. CEPI’s investment case may be accessed at https://endpandemics.cepi.net CEPI also receives public donations through the UN Foundation COVID-19 Solidarity Response Fund: https://covid19responsefund.org/ 10 million Lives were saved between 2010 and 2015 thanks to vaccines. (WHO, 2017) $53 billion The cost of the 2014 Ebola epidemic in west Africa. (C Huber et al, 2018) $570 billion The estimated annual global cost of moderately severe to severe pandemics (World Bank, 2017) $2.8 billion The average minimum cost for progressing one vaccine against each of WHO’s 11 priority epidemic infectious diseases. (D Gouglas et al, 2018) Progress Support from donors CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum. To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome. Additionally, CEPI has also received support from private sector entities as well as public contributions through the UN Foundation COVID-19 Solidarity Response Fund. Calls for Proposals successfully announced Since our launch in 2017, CEPI has announced a number of Calls for Proposals to support the development of candidate vaccines against Middle East Respiratory Syndrome coronavirus (MERS-CoV), Nipah virus, Lassa virus, Rift Valley fever virus, and Chikungunya viruses, as well as rapid-response technologies to develop vaccines against Disease X. During this period, CEPI has also overseen several scientific breakthroughs in developing vaccines against other infectious diseases, including the first phase 3 trial of a Chikungunya vaccine and the advancement of the first ever Nipah virus and Lassa virus vaccines into phase 1 clinical trials. Working on COVID-19 vaccine programmes CEPI has played a central role in the global response to COVID-19, creating the world’s largest portfolio of COVID-19 vaccines and helping to make 2 billion doses equitably accessible to 190 participating economies through COVAX in 2021. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine. CEPI is also investing in the ‘next generation’ of vaccine candidates, which will give the world additional options to control COVID-19 in the future. The Australian Government is invested in the global effort to fund critical research and development gaps for pandemic preparedness and global health security. Australia is committed to global health, and will continue to build global innovative partnerships and seek out opportunities for international research collaboration. Australia’s contribution to the Coalition of Epidemic Preparedness Innovations, through the Medical Research Future Fund, will assist in the development of vital vaccines suitable for humans that are deploy-ready before an epidemic begins, and ensure we are prepared for future epidemics. Government of Australia CEPI has helped the global science community do something incredible: develop COVID-19 vaccines in less than a year. With the right support, CEPI will continue to accelerate innovation and achieve breakthroughs, helping ensure that everyone has equitable access to lifesaving vaccines. Bill Gates, Co-Chair Bill and Melinda Gates Foundation INVEST NOW Work with CEPI Funding opportunities We create innovative partnerships between public, private, philanthropic, and civil organisations to develop vaccines against diseases with epidemic potential. We invest in promising vaccine candidates against our priority pathogens and platform technologies that can enable rapid development of vaccines against new and unknown pathogens. We also coordinate activities to improve our collective response to epidemics. Learn more about our funding opportunities. CALLS FOR PROPOSALS We are supporting all areas of vaccine science. CEPI is investing in vaccine-based solutions that not only protect some of the most vulnerable people in the world but will also help to prevent future pandemics. Get in touch to find out how your organisation could work with CEPI. Contact us Work at CEPI Our world-class multidisciplinary team is working to create a future in which epidemics are no longer a threat to Humanity. Want to join the team? Open positions Follow our work From the lab to the clinic, CEPI and its partners are working around the clock to accelerate the development of vaccines against emerging infectious diseases. Follow our latest news. News & stories Subscribe to our newsletter I agree with the Ts & Cs CEPI’S $3.5 BILLION PLAN TO END PANDEMICS PROGRESS WORK WITH CEPI WORK AT CEPI FOLLOW OUR WORK ABOUT US Why we exist Mission Approach Who we are Overview Leadership Board Investors & Partners Scientific Advisory Committee Joint Coordination Group Antiracism statement Anti-Slavery Statement Governance Articles of association Board Meeting Summaries Board of Directors' report, annual accounts and Auditor's statement Business Plan CEPI Policies Equitable Access Financial Internal policies Investors Council Joint Coordination Group Members Meetings Other Guidance for Awardees Scientific Advisory Committee Strategy & Progress Terms of reference GET INVOLVED Support CEPI Invest in CEPI Progress Work with CEPI Work at CEPI Follow our work Calls for Proposals RESEARCH & DEVELOPMENT Our portfolio Platform Technology Priority diseases MERS Lassa Nipah Disease X Rift Valley fever Chikungunya Ebola Vaccine science Biological Standards, Assays & Animal Models Collect vaccine data Researching emerging infectious diseases INFO & ACTION News & stories Outbreaks Careers Contact Social LinkedIn Twitter Legal Terms of use Privacy policy Procurement tenders Reporting Concern ©2021 CEPI. All rights reserved